Population pharmacokinetics of erlotinib in Japanese patients with advanced non‐small cell lung cancer

E-ISSN： 1365-2710|40|2|232-239

ISSN： 0269-4727

Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.40, Iss.2, 2015-04, pp. : 232-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized phase 2 trial of erlotinib in combination with high‐dose celecoxib or placebo in patients with advanced non‐small cell lung cancer

CANCER, Vol. 121, Iss. 18, 2015-09 ,pp. : 3298-3306

John Wiley & Sons Inc

Access to resources Recommend Favorite

Erlotinib after Failure of Gefitinib Treatment of More Than 6 Months in Advanced Non-Small Cell Lung Cancer

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 8-9

Karger

Access to resources Recommend Favorite

Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 182-191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Elderly Patients with Advanced Non-Small Cell Lung Cancer

Oncology, Vol. 65, Iss. 3, 2003-12 ,pp. : 198-203

Karger

Access to resources Recommend Favorite

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite